Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancerQian Zhou, Liang Chen, Jinxia Liang et al.|EMBO Molecular Medicine|2021Cited by 56
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).María‐Victoria Mateos, Vânia Hungria, Vera Zherebtsova et al.|Journal of Clinical Oncology|2024Cited by 21